YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024
GAITHERSBURG, Md., Jan. 22, 2024 /PRNewswire/ — YS Biopharma Co., Ltd. (NASDAQ: YS) (“YS Biopharma”) along with its subsidiaries (“YS Group” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its unaudited consolidated financial results for the first half of the fiscal year ended March 31, 2024 (the “first half of fiscal year 2024”).
Related news for (YS)
- MoBot’s Stock Market Highlights – 10/24/25 03:00 PM
- Friday the 14th Follow-Up: $14 Fever Sweeps the Street
- Theriva Biologics Provides Response to Unusual Market Action
- Majority Grindr Shareholders George Raymond Zage III and James Fu Bin Lu Submit Non-Binding Offer to Acquire All Outstanding Shares of Grindr Inc. for $18.00 per Share
- Don’t Miss Out: MoBot’s Latest Stock Updates 10/24/25 02:00 PM
